Skip to main content
Skip to content
Case File
efta-efta00299761DOJ Data Set 9Other

BioReference

Date
Unknown
Source
DOJ Data Set 9
Reference
efta-efta00299761
Pages
4
Persons
0
Integrity
No Hash Available

Summary

Ask AI About This Document

0Share
PostReddit

Extracted Text (OCR)

EFTA Disclosure
Text extracted via OCR from the original document. May contain errors from the scanning process.
BioReference PRELIMINARY L Aar,,, ,: ATC: 9 I ES C/PKO ORSHER, STUART C3070 - STUART ORSHER, M.D. 9 EAST 79TH ST, NEW YORK, NY 18021 Acct P. PO IIIII EPSTEIN, JEFFREY D08: 41/20/1953 Age:64 V skate i U/FL: Bed: RM: Patient 10: Address:9 EAST 71ST STREET. INW YORK, HY 10021 P: Dotes: NON FASTING NOTE: SST tube submitted was inadequately spun. Serum was found to contain ReCs. Certain tests, e.g. Glucose, nay be decreased while ethers e.g. Potassium or LOH may be elevated. Specimen I' 104659439 Date Of APport.,,f44414NOP-65:29 Date Collected: 09/19/2017 08:57 Date Received: 09/15/2017 23:06 Ateth MiltriCO EOS tern rime CLINICAL REPORT (Nay not contain all abnormal results: narrative results say not have abnormal Clinical Abnormalities Summary: flags. Please review entire report.) Cholesterol 224 HI Triglycerides 646 HI HDL CHOL., DIRECT 29 LO HEN as % of 13 • rhol/HOL Ratio 7.7 NON-HDL 115 HI Cholesterol CHOLESTEROL HEP. A Ab., TOTAL Reactive HEP. B SURF. A3. Reactive 250H, VITAMIN D 31.5 LO PTH(3), INTACT 106.0 HI Albumin Calcium -- 4.7 3.5.5.2 g/dL ---.. -.e/di. CARDIOVASCULAR/LIPIDS "-- 4.5 08/30/2017 1RVAW:felY"' Cholesterol iTriayearides NOL CHOL., DIRECT MK as % of cholesterol 13 • >la •.• it Evaluation: MOVE AVO.(PODERATE RISK) :Chol/HDL Ratio 7.7 • <7.4 Evaluation: ABOVE 4vG.(RODERATE RISK) rlDIVA0L Aiii0 " - 0.0L%Chelestendk . can't calc Can't Cili <100 <3.50 iiT&-- Cortrinta - ::13:::71. , iNON.HDL CHOLESTEROL 195 HZ <130 . . . . i. ISSTEit:imable to calculate 101 dojos a Triglyceride lent of greater then 400agidt, . . .0.6C—CALCULATED Can't Calc 7-32 mg/dL f Can't adc TOSV2017 doe <150 >40 ragiar. .471 S at HZ mg/dL mg/dL TRIP 'INP MP 08/30/2017 0E/30/2017 : 08/30/2017 08/3437Trir2 1 1 08/3e/2917., can't Calc: One or more components was outside the measurable range. We are unable to calculate. 794 THVROXINE(T4) 1.770 SioReference Laboratories, Inc. 481 Edward H. Ross OP I elmmoon Park. N/07487 I 0.178-4.530 u1U/aL 4.9.121 ustiE 08/30/2017 EN/30/3017 James Weisberger M.D. Page 1 of 4 Laboratory Director printed 09/19/2017 11:48 EFTA00299761 BioReference ABORATORiES er OPKO Hecon Convene ORSHER, STUART 3078 - STUART ORSHER, M.D. 9 EAST 79TH ST, NEW YORK, NY 10021 Acct #: (03870) P. CLINICAL REPORT MO EPSTEIN, JEFFREY -----) DOB: 01/26/1953 Age: 64 V Six: M U/Fl: Bed: Rm: Patient ID: Address:, EAST Tut STREET, NEW YORK, NY 10021 11: -- eve IM a bodies say occasionally pees ct for more than 12 --months post-infection. i --Test developed and characteristics determined by ARDS Laboratories. See Compliance Statement A: eruplab.com/Cs --www.aruplab.com, lull.° Delgado, MD - Lab. Director • B. quintana Ab, IgG <1:64 i --INTERPRETIVE MS092447104: Bartonella quintana Antibody, IgG Less than 1:64 Negative: No significant level of I .. Bartonella quintana XgG antibody detected. ; 1:64 - 1:123 Equivocal: Questionable presence of Bartonella quintana IgG antibody detected. Repeat tasting in 10-14 days may be helpful. :• 1466 or greater Positive: Presence of /6 -- antibody to Bartonella quintana detected, suggestive of current or past infection. . --A IOW:positive suggests past exposure or infection, while high --positive results may indicate recent or current infection, but is --inconclusive. for diagnosis. Seroconversion between acute and -=convalescent sera is considered strong evidence of recent ; -infection. The best evidence for infection is a significant change two appropriately timed specimens where both tests are done in --the same laboratory at the same time. --Test developed and characteristics determined by ARUP --Laboratories. See Coepliance Statement A: aruplab.com/CS Nip. dil. Noe: Reactive 0.03 Ab. (S/C0 RATIO) ! • PerforMed by: ARUP 500 Chipeta Nay Salt Lake City, UI 8.41013 Hepatitis B Result Interpretation (for reference use only) NOD-Riective . 41.80 Marker See. Li/EA* Acute Past Chronic RSV issAg + + + NBeAe + + +/- NIP.B.,CORE A6,IgM + - tRIP.ECORE AB. + + + Warn: +/- +/- . +/- + *LateIntileation/Early Acute NOTE: In remote past infection, H9sAb level may be Negative or BioReference laboratories, Inc. 481 Edward H. Ross D- I Elmwood Park. N) 07407 PRELIMINARY Specimen ID: 104659439 Date Of Report: 09/19/2917 05:29 Date Collected: 09/15/2017 08:57 Date Received: 09/15/2017 23:06 North America Eastern 7itte JarnesWeiabergorld.D. Page 3 of 4 Laboratory Director Printed 09/19/2017 11:48 EFTA00299762 BioReference PRELIMINARY : Al:ORATORI ES an OPKO HasIth Company ORSNER, STUART C3070 - STUART ORSHER, M.D. 9 EAST 79TH ST. NEW YORK, NY 18021 Ct 8: (C3070) P: CLINICAL REPORT EPSTEIN, iEFFREY DOB: 01/20/1953 Ago: 64 V Sex: M /FL: Bed: Patient xo: Address:9 EAST 71ST STREET, NEW YORK, NY 20021 FOLIC ACID 7.77 Tap -101110/i617— .. >5.38 Folic Acid Range Units (ng/mli Normal >5.38 Borderline deficient 3.38.5.38 Deficient 0.35-3.37 Excessive >24.00 359 .150K, IfITEX/N D _ . . : VITAMIN 0,25-00 TEST INFORMATION Range (ng/mL) <20.0 20.0-31.9 32.0-100.0 >100.8 'Mt "' INTACT ;Aiuko-nb T Oi b (58) ArTgi, — Alkupt Ab tipe 8 (si) PNEUMO AD TYPE 9 (9N) (58) (*MSC 0 TYPE 12 (12P) (58) ifsNEUMO Ab TYPE 14 (58) * OrimUMO-A*O-ttOkii* (IOW (51) * 41**(23)** (MO' I Specimen ID: 104659439 Date Of Report: 09/19/2017 05:29 Date Collected: 09/15/2017 08:57 Date Received: 09/15/2017 23:06 North asertco foster,' nee . . 31.8 LO nth& Suggested Interpretation Deficient Insufficient Sufficient Possible Adverse Effects 52.0 ' 19.9-7.4 pest 106.0 HI 13.8-85.0 pg/mL TO POLE TO FOLLOW -16 TO FOLLOW TO FOLLOW TO FOLLOW TO FOLLOW TO FOLLOW' - ro POLLai PNEUMO Ab TYPE 26 SO tss) to OoLLow PNEUMO Ab TYPE 5'(58) TO FOLLOW PNEUMO Ab TYPE Si (7F) (58)." 000•61 IFINEUND'Ab TYPE 56: (18C) (58) TO FOLLOW ;ONEOMO ii*,*tyPE (58) TO t i4ense5i-Triirar Ab (3) TO FOLLOW . <0.3 LO 4.4 -- 0.4 Le 0.4 LO (0.3 LO 23.2 8.8 LO 48;3 LO 8.5 lo 7.8 is 1.3 LO 0.4 LO • 96/30/2017 08/34/2017 OBA7/5317 : 08/30/2017 00/30/2017 08/30/2017 00/30/2017 08/30/2017 eniSehr ea/se/atir: 08/30/2017 08/30/2817 06/30%2017 08/30/2017 08/30/2017 NOTE: Specimen submitted is LIPEMIC. This may cause inaccurate results. Please resubmit a fasting specimen at your earliest convenience. sloReference Laboratories, Inc. 481 Edward H. Ross Dr I Elmwood Park, NT 07407 I ea/seneii JnosembYelebergmrhILD. Page 4 of 4 LaboratoryDirector Printed 09/19/2017 11:48 EFTA00299763 EFTA00299764

Technical Artifacts (8)

View in Artifacts Browser

Email addresses, URLs, phone numbers, and other technical indicators extracted from this document.

Domainaruplab.com
Domaineruplab.com
Domainwww.aruplab.com
IPv43.38.5.38
IPv613::
Phone2447104
Phone4659439
Wire Refreference

Forum Discussions

This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.

Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.